MedTrace Logo

Efficacy of Ondansetron in LARS Treatment

NCT03182179 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-10-17

No results posted yet for this study

Summary

Patients will be randomized (1:1 ratio) to receive either 4 weeks of Ondansetron followed by 4 weeks of placebo (O-P sequence) or 4 weeks of placebo followed by 4 weeks of Ondansetron (P-O sequence). It will be one week of washout between the two treatments.

During the treatment questionnaires will be completed by the patients to evaluate the efficacy of the study treatment and the quality of live.

Conditions

Interventions

DRUG

Ondansetron 4 MG

Ondansetron is taken orally BD

DRUG

Placebo

Placebo is taken orally BD

Sponsors & Collaborators

  • Ente Ospedaliero Cantonale, Bellinzona

    lead OTHER

Principal Investigators

  • Dimitri Christoforidis, Prof. · Ospedale Regionale di Lugano, Civico e Italiano

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-01
Primary Completion
2021-11-19
Completion
2021-11-19

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03182179 on ClinicalTrials.gov